

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal

Use of tumour necrosis factor alpha (TNF α) inhibitors (adalimumab, certolizumab and infliximab [review]) and natalizumab for Crohn's disease

Response to consultee and commentator comments on the provisional matrix of consultees and commentators

No comments were received on the provisional matrix.

Alana Miller
April 2007